The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.
Economic evaluations
Health technology assessment
Immunization
Public health
Research and development
Vaccines
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
04 07 2023
04 07 2023
Historique:
received:
18
10
2022
accepted:
08
06
2023
medline:
5
7
2023
pubmed:
4
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Several economic obstacles can deter the development and use of vaccines. This can lead to limited product options for some diseases, delays in new product development, and inequitable access to vaccines. Although seemingly distinct, these obstacles are actually interrelated and therefore need to be addressed through a single over-arching strategy encompassing all stakeholders. To help overcome these obstacles, we propose a new approach, the Full Value of Vaccines Assessments (FVVA) framework, to guide the assessment and communication of the value of a vaccine. The FVVA framework is designed to facilitate alignment across key stakeholders and to enhance decision-making around investment in vaccine development, policy-making, procurement, and introduction, particularly for vaccines intended for use in low- and middle-income countries. The FVVA framework has three key elements. First, to enhance assessment, existing value-assessment methods and tools are adapted to include broader benefits of vaccines as well as opportunity costs borne by stakeholders. Second, to improve decision-making, a deliberative process is required to recognize the agency of stakeholders and to ensure country ownership of decision-making and priority setting. Third, the FVVA framework provides a consistent and evidence-based approach that facilitates communication about the full value of vaccines, helping to enhance alignment and coordination across diverse stakeholders. The FVVA framework provides guidance for stakeholders organizing global-level efforts to promote investment in vaccines that are priorities for LMICs. By providing a more holistic view of the benefits of vaccines, its application also has the potential to encourage greater take-up by countries, thereby leading to more sustainable and equitable impacts of vaccines and immunization programmes.
Sections du résumé
BACKGROUND
Several economic obstacles can deter the development and use of vaccines. This can lead to limited product options for some diseases, delays in new product development, and inequitable access to vaccines. Although seemingly distinct, these obstacles are actually interrelated and therefore need to be addressed through a single over-arching strategy encompassing all stakeholders.
METHODS
To help overcome these obstacles, we propose a new approach, the Full Value of Vaccines Assessments (FVVA) framework, to guide the assessment and communication of the value of a vaccine. The FVVA framework is designed to facilitate alignment across key stakeholders and to enhance decision-making around investment in vaccine development, policy-making, procurement, and introduction, particularly for vaccines intended for use in low- and middle-income countries.
RESULTS
The FVVA framework has three key elements. First, to enhance assessment, existing value-assessment methods and tools are adapted to include broader benefits of vaccines as well as opportunity costs borne by stakeholders. Second, to improve decision-making, a deliberative process is required to recognize the agency of stakeholders and to ensure country ownership of decision-making and priority setting. Third, the FVVA framework provides a consistent and evidence-based approach that facilitates communication about the full value of vaccines, helping to enhance alignment and coordination across diverse stakeholders.
CONCLUSIONS
The FVVA framework provides guidance for stakeholders organizing global-level efforts to promote investment in vaccines that are priorities for LMICs. By providing a more holistic view of the benefits of vaccines, its application also has the potential to encourage greater take-up by countries, thereby leading to more sustainable and equitable impacts of vaccines and immunization programmes.
Identifiants
pubmed: 37400797
doi: 10.1186/s12916-023-02929-0
pii: 10.1186/s12916-023-02929-0
pmc: PMC10318807
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2023. The Author(s).
Références
BMC Public Health. 2012 Oct 16;12:878
pubmed: 23072714
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):
pubmed: 29530951
Appl Health Econ Health Policy. 2016 Jun;14(3):245-52
pubmed: 26832145
Milbank Q. 2021 Jun;99(2):426-449
pubmed: 33650737
Vaccine. 2017 Nov 1;35(46):6255-6263
pubmed: 28986035
Value Health. 2016 Dec;19(8):921-928
pubmed: 27987641
Value Health. 2021 Aug;24(8):1150-1157
pubmed: 34372981
Am J Bioeth. 2006 May-Jun;6(3):3-6
pubmed: 16754439
Cost Eff Resour Alloc. 2003 Dec 19;1(1):8
pubmed: 14687420
Value Health. 2019 Aug;22(8):942-952
pubmed: 31426936
Lancet Glob Health. 2023 Apr;11(4):e546-e555
pubmed: 36925175
BMC Med. 2015 Sep 03;13:209
pubmed: 26335923
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 32198269
Clin Infect Dis. 2022 Jan 20;74(Suppl_1):S1-S4
pubmed: 34725691
Vaccine. 2011 Mar 16;29(13):2371-80
pubmed: 21159324
Pharmacoeconomics. 2016 Sep;34(9):913-23
pubmed: 27374172
Am J Bioeth. 2012;12(12):35-54
pubmed: 23215931
Pharmacoeconomics. 2011 May;29(5):371-86
pubmed: 21504239
Lancet Infect Dis. 2008 Nov;8(11):727-33
pubmed: 18992409
Int J Health Policy Manag. 2021 Nov 01;10(11):673-677
pubmed: 33619929
Vaccine. 2022 Mar 15;40(12):1681-1690
pubmed: 35164990
BMC Med. 2022 Mar 8;20(1):88
pubmed: 35255920
Nat Rev Microbiol. 2008 Jun;6(6):477-87
pubmed: 18533288
Clin Infect Dis. 2021 Aug 16;73(4):e1011-e1017
pubmed: 33493317
Health Aff (Millwood). 2016 Feb;35(2):227-34
pubmed: 26858374
Lancet Public Health. 2021 Jun;6(6):e428-e433
pubmed: 33964227
Med Decis Making. 2012 Sep-Oct;32(5):712-21
pubmed: 22990086
Int J Health Policy Manag. 2016 Aug 29;6(4):233-236
pubmed: 28812807
PLoS One. 2020 Jun 10;15(6):e0233950
pubmed: 32520934
Value Health. 2016 Jan;19(1):1-13
pubmed: 26797229
Influenza Other Respir Viruses. 2018 Jan;12(1):13-21
pubmed: 29143498
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Value Health. 2007 Sep-Oct;10(5):336-47
pubmed: 17888098
Value Health. 2019 Jan;22(1):13-20
pubmed: 30661627
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S111-S119
pubmed: 32725239
Vaccine. 2012 Dec 17;31(1):96-108
pubmed: 23142307
Nature. 2019 Nov;575(7781):119-129
pubmed: 31695203